Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 79INDUSTRY 18NIH 10NETWORK 3UNKNOWN 1OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 42Esophageal Neoplasms 24Stomach Neoplasms 21Rectal Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Colorectal Neoplasms 12Neoplasms 10Brain Neoplasms 10Triple Negative Breast Neoplasms 9Lung Neoplasms 9Small Cell Lung Carcinoma 8Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Hepatocellular 5Recurrence 4Radiation Injuries 4Nasopharyngeal Carcinoma 4Melanoma 4Lymphoma, Extranodal NK-T-Cell 4Head and Neck Neoplasms 4Uterine Cervical Neoplasms 3Meningeal Carcinomatosis 3Lymphoma 3Leukemia, Myeloid, Acute 3Hormone Receptor Positive Advanced Breast Cancer 3HER2-positive Breast Cancer 3Colonic Neoplasms 3Vomiting 2

Interventions

Thalidomide 1Temozolomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Adenoma, Islet Cell × Clear all
NCT03204019 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡